AUSTIN, TX / ACCESS Newswire / March 2, 2026 / In modern metabolic medicine, few treatments have reshaped care like GLP-1 receptor agonists. If you are asking what is semaglutide, it is a prescription ...
Successfully started 216 patients on IBTROZI® (taletrectinib) in the fourth quarter of 2025, for a total of 432 new patient starts since launch in the ...
Genetix delivers strong 2025 revenue growth resulting in the Company’s first ever profitable quarterIn 2025, >100 U.S. patients were treated and >150 U.S. patients completed their first cell ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results